NewAmsterdam Pharma Co N.V.
- Close
- Jun 30, 2026
- Market cap
- —
- no share count on file
- Filings
- 417
Q3 2026−50.6% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−36.5% FY25 yoy
Price
Jun 30, 2026 · 13F quarter end
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $22,503,000 | reported | |
| FY 2024 | 2024-12-31 | $45,563,000 | reported | |
| FY 2023 | 2023-12-31 | $14,090,000 | reported | |
| FY 2022 | 2022-12-31 | $102,694,000 | reported |
Pharmaceutical preparations
NewAmsterdam Pharma Co N.V. is the 151st largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
CUECue Biopharma, Inc.$27.5M195.7%96.9%$128.4MCELUCelularity Inc$26.6M51.0%345.4%$21.8MTRDAEntrada Therapeutics, Inc.$25.4M87.9%565.5%$203.2MALMSAlumis Inc.$24.1M—1,011.7%$796.5M
NAMSWNewAmsterdam Pharma Co N.V. (this company)$22.5M50.6%905.7%$2.4B
CASIFCASI Pharmaceuticals, Inc.$20.7M27.4%232.0%$3.1MSCYXScynexis Inc$20.6M449.9%41.8%$32.9MEVFMEvofem Biosciences, Inc.$20.2M4.2%1.9%$1.3MSLGLSol-Gel Technologies Ltd.$19.4M68.0%31.6%$156.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
NewAmsterdam Pharma Co N.V. · CIK 1936258 · Engraved from SEC EDGAR